# Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.

> **NCT06772064** · NA · RECRUITING · sponsor: **Xiuli Zuo** · enrollment: 115 (estimated)

## Conditions studied

- SIBO

## Interventions

- **DRUG:** Rifaximin (drug)

## Key facts

- **NCT ID:** NCT06772064
- **Lead sponsor:** Xiuli Zuo
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06772064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06772064, "Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06772064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*